The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. The products discussed herein may have different product labeling in different countries.
BARRIGEL® is used to increase the distance between the prostate and the anterior rectal wall, with the intent to decrease radiation dose delivered to the rectum when treating prostate cancer with radiation. Talk to your doctor if you are allergic to hyaluronic acid-based products. There are adverse effects that can happen: mild to moderate sensation of rectal filling, injection site discomfort, injection site irritation, injection site bleeding or hematoma, injection site inflammation, infection, dysuria or a weak urine stream. Talk to your doctor about these adverse effects. BARRIGEL is contraindicated in prostate cancer patients with clinical stage T4. Please see complete Prescribing Information for BARRIGEL.
In the EU, Q-Med is the current legal manufacturer and holds the CE Mark.
BARRIGEL is not approved for sale in the United States.
BARRIGEL® and NASHA® are registered trademarks.